Jakob Lindberg
Chief Executive Officer
Medical Science
Oncopeptides
Sweden
Biography
Jakob Lindberg was appointed as CEO in 2011. In addition to being CEO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, part of the Investor AB group of companies. Jakob’s previous roles include being an analyst for Merrill Lynch & Co and a consultant at McKinsey&Co. Jakob also co-founded Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO. Jakob studied medicine at the Karolinska Institute where he also gained a Med Lic in Molecular Immunology and an MSc in pre-clinical medicine. He also has a BA in Finance and Administration from Stockholm University. Born: 1972 Holdings in Oncopeptides: 235 409 shares (220,109 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB) and 1,070 Share Options* Other current positions: Director of Affibody Medical AB, Alligator Bioscience AB, Atlas Antibodies AB, Dipylon Medical AB, Lindberg Life-Science AB and Bostadsrättsföreningen Astraea. Alternate Director of Oncopeptides Incentive AB. CEO of Lindberg Life-Science AB.
Research Interest
His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.
